• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Menopausal hormone therapy use in 17 European countries during the last decade
The first ‘Women's Health Initiative’ (WHI) randomised controlled trial assessed use of continuous combined menopausal hormone therapy (cc-MHT). It was prematurely stopped because of an increased invasive breast cancer (BC), coronary heart disease (CHD), stroke and pulmonary embolism risk. Consequently, scientific societies recommended use of MHT at the lowest effective dose for the shortest duration. As a result, a sharp decline in MHT use occurred worldwide.
Source: Maturitas - August 4, 2014 Category: Primary Care Authors: Lieveke Ameye, Caroline Antoine, Marianne Paesmans, Evandro de Azambuja, Serge Rozenberg Source Type: research

Health in older women athletes
Physical activity is commonly recognized as healthy behavior and an important part of modern life. A large body of evidence shows that regular physical activity plays a protective role against the development of several conditions, such as cardiovascular disease (hypertension and thromboembolic stroke), type 2 diabetes, osteoporosis, obesity, colon cancer, breast cancer and psychiatric illness (depression and anxiety) [1]. Recently, some evidence has been found concerning a negative correlation between physical activity and cognitive decline among women [2].
Source: Maturitas - September 14, 2014 Category: Primary Care Authors: Blazej Meczekalski, Krzysztof Katulski, Adam Czyzyk, Agnieszka Podfigurna-Stopa Tags: Review Article Source Type: research

Menopausal hormone therapy use in 17 European countries during the last decade
The first ‘Women's Health Initiative’ (WHI) randomised controlled trial assessed use of continuous combined menopausal hormone therapy (cc-MHT). It was prematurely stopped because of an increased invasive breast cancer (BC), coronary heart disease (CHD), stroke and pulmonary embolism risk. Consequently, scientific societies recommended use of MHT at the lowest effective dose for the shortest duration. As a result, a sharp decline in MHT use occurred worldwide.
Source: Maturitas - August 4, 2014 Category: Primary Care Authors: Lieveke Ameye, Caroline Antoine, Marianne Paesmans, Evandro de Azambuja, Serge Rozenberg Source Type: research

Menopausal hormone therapy and ovarian cancer: putting risk into perspective
The wide use of menopausal hormone therapy (MHT) rapidly declined a decade ago after the results of the Women's Health Initiative (WHI) showed that women treated with conjugated equine estrogens plus medroxyprogesterone acetate had an increased risk of breast cancer, coronary heart disease, stroke, and pulmonary embolism [1]. Increased ovarian cancer risk was not reported in the randomized WHI intervention trial nor in the extended poststopping phases of the study [2].
Source: Maturitas - February 26, 2015 Category: Primary Care Authors: Faustino R. Pérez-López, Margaret Rees Source Type: research

Menopausal hormone therapy use in 17 European countries during the last decade
Introduction: The first ‘Women's Health Initiative’ (WHI) randomised controlled trial assessed use of continuous combined menopausal hormone therapy (cc-MHT). It was prematurely stopped because of an increased invasive breast cancer (BC), coronary heart disease (CHD), stroke and pulmonary embolism risk. Consequently, scientific societies recommended use of MHT at the lowest effective dose for the shortest duration. As a result, a sharp decline in MHT use occurred worldwide.
Source: Maturitas - April 21, 2015 Category: Primary Care Authors: Lieveke Ameye, Caroline Antoine, Marianne Paesmans, Evandro de Azambuja, Serge Rozenberg Tags: O44 Source Type: research

Menopausal hormone therapy, depression, headache, vasomotor symptoms and absence from work: results from 3 years follow up in a Dutch gynecology clinic
Introduction: Use of menopausal hormone therapy (MHT) has dropped worldwide during the last decade after the ‘Women's Health Initiative’ (WHI) trial reported increased breast cancer, stroke and embolism risk. Women with bothersome menopausal complaints resorted to complementary and alternative medications with less or unproven efficacy. Even when indicated use of MHT is low and of short duration, possibly affecting individual wellbeing and ability to work.
Source: Maturitas - April 21, 2015 Category: Primary Care Authors: Mojdeh Shayesteh, Ingrid Pinas Tags: O5 Source Type: research

Hormone therapy and venous thromboembolism among postmenopausal women
Despite a decrease in postmenopausal hormone therapy (HT) use during the last decade, many women are still prescribed this treatment which remains the most effective to counteract climacteric symptoms. However, HT increases the risk of breast cancer, stroke and venous thromboembolism (VTE) which represents the major harmful effect of short-term duration use. Nevertheless, this benefit/risk ratio has been established among women using oral estrogens alone or combined with a specific progestogen and cannot be necessary extrapolated to other HT.
Source: Maturitas - April 21, 2015 Category: Primary Care Authors: Marianne Canonico Tags: INV32 Source Type: research

A Clinical Prescription for Heart Health in Midlife Women
Heart disease remains the leading cause of death in women in Europe and the United States with the incidence increasing during midlife. [1] While one in thirty-one women will die from breast cancer, one in approximately two to three women will die from heart disease or stroke. [1,2], While most women are aware about traditional cardiovascular disease (CVD) risk factors, such as hypertension, dyslipidemia and diabetes, they are often unaware of sex specific risk factors that occur in midlife. [3] Clinical risk factors can vary depending on the individual personal family history and can change as a woman ages.
Source: Maturitas - November 12, 2018 Category: Primary Care Authors: Chrisandra Shufelt, Erika Dutra, Tina Torbati, Tina Ramineni Source Type: research

Problem-patients in HRT
Since the Women's Health Initiative (WHI) has been stopped 2002 due to increased risk of venous thromboembolism, myocardial infarction, stroke and breast cancer, safety issues have got great concern using hormone replacement therapy (HRT). However, using lower dosages, other hormonal components and/or transdermal instead of oral application can reduce those risks although not demonstrated in a placebo-controlled study comparable to WHI. However, this has been shown in large case/control- and cohort-studies reflecting more practical conditions in contrast to WHI.
Source: Maturitas - May 14, 2019 Category: Primary Care Authors: Alfred O. Mueck Tags: INV65 Source Type: research